surmount studies tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for maintenance of bodyweight
Pay in 4 interest-free payments of $6.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
![surmount studies tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for maintenance of bodyweight](https://www.thelancet.com/cms/10.1016/S0140-6736(23)01200-X/asset/1ec2c191-5a64-4856-842f-bfa65a8fabc6/main.assets/gr2.jpg)
![surmount studies tirzepatide In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for maintenance of bodyweight](https://www.nejm.org/cms/10.1056/NEJMoa2410819/asset/01b1d3fc-578b-464e-bfe2-55fe16a74f42/assets/images/large/nejmoa2410819_f1.jpg)





















